(Q38019864)

27 August 2017

title

Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development (English)

1 reference

27 August 2017

Eva Maria Huber

1

1 reference

27 August 2017

Michael Groll

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

18 June 2012

1 reference

Angewandte Chemie International Edition

27 August 2017

published in

0 references

volume

51

1 reference

27 August 2017

issue

35

1 reference

27 August 2017

page(s)

8708-8720

1 reference

Recognition and processing of ubiquitin-protein conjugates by the proteasome

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Regulation of CD8+ T cell development by thymus-specific proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Proteasome and peptidase function in MHC-class-I-mediated antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

A third interferon-gamma-induced subunit exchange in the 20S proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Proteasomes in immune cells: more than peptide producers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Mice completely lacking immunoproteasomes show major changes in antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

MHC class I expression in mice lacking the proteasome subunit LMP-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Thymoproteasome: probable role in generating positively selecting peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

A protein catalytic framework with an N-terminal nucleophile is capable of self-activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Proteasome from Thermoplasma acidophilum: a threonine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Structure of 20S proteasome from yeast at 2.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

The structure of the mammalian 20S proteasome at 2.75 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

20S proteasome and its inhibitors: crystallographic knowledge for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Exploiting nature's rich source of proteasome inhibitors as starting points in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Proteasome inhibitors: an expanding army attacking a unique target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Prevention of experimental colitis by a selective inhibitor of the immunoproteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Crystal structure of heat shock locus V (HslV) from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Mechanisms of proteasome inhibitor action and resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

LMP2-specific inhibitors: chemical genetic tools for proteasome biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Expression of catalytic proteasome subunits in the gut of patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Transformation of the proteasome with age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Assessing the role of immuno-proteasomes in a mouse model of familial ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Enhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

The immunoproteasome: an emerging therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

A transgenic mouse model of the ubiquitin/proteasome system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Strategies for the inhibition of serine proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Elucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Proteasome structure, function, and lessons learned from beta-lactone inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Geometrical reaction coordinates. II. Nucleophilic addition to a carbonyl group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Nature of pharmacophore influences active site specificity of proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Bortezomib for the treatment of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Bortezomib in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Novel proteasome inhibitors to overcome bortezomib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Approval summary for bortezomib for injection in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Epoxomicin, a new antitumor agent of microbial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Molecular mechanisms of bortezomib resistant adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Molecular pathways: targeting proteasomal protein degradation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

Hydroxyureas as noncovalent proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201201616

TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities.

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.53.105

Identifiers

DOI

10.1002/ANIE.201201616

1 reference

27 August 2017

1 reference